Literature DB >> 18005871

Altered expression of early cardiac marker genes in circulating cells of patients with hypertrophic cardiomyopathy.

Joanna E Kontaraki1, Fragiskos I Parthenakis, Alexandros P Patrianakos, Ioannis K Karalis, Panos E Vardas.   

Abstract

BACKGROUND: Early cardiac marker genes, such as cardiac-specific homeobox (Csx/Nkx2.5), myocardin, homeodomain only protein, GATA4, and myocyte enhancer factor 2C, are thought to participate in cardiomyocyte differentiation and to contribute to heart hypertrophy in animal models. In this study, we investigated whether the expression of early cardiac genes is altered in the peripheral blood of patients with hypertrophic cardiomyopathy.
METHODS: Peripheral blood mononuclear cells were isolated from 30 consecutive hypertrophic cardiomyopathy patients and 20 healthy controls, and gene expression was determined by quantitative real-time reverse transcription-polymerase chain reaction.
RESULTS: Csx/Nkx2.5, myocardin, and GATA4 expressions were significantly higher in hypertrophic cardiomyopathy patients by 5.14+/-0.89 (P<.001), 1.65+/-0.21 (P<.05), and 2.04+/-0.41 (P<.04) times, respectively, while homeodomain only protein showed a fourfold decrease in expression (P<.02) compared to controls. In addition, expression of the differentiation-specific marker genes beta-myosin heavy chain and smooth muscle myosin heavy chain was significantly higher in hypertrophic cardiomyopathy patients by 3.72+/-0.82 (P<.02) and 2.57+/-0.72 (P<.05) times, respectively, compared to controls. Myocyte enhancer factor 2C expression was not different between patients and controls. Furthermore, increased expression of GATA4, myocardin, and beta-myosin heavy chain positively correlated with increased left ventricular mass.
CONCLUSIONS: In conclusion, we found altered expressions of early cardiac marker genes and differentiation-specific marker genes in peripheral blood mononuclear cells of hypertrophic cardiomyopathy patients compared to control individuals, possibly reflecting changes in response to disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005871     DOI: 10.1016/j.carpath.2007.04.004

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  13 in total

1.  Hyperoxia-induced hypertrophy and ion channel remodeling in left ventricle.

Authors:  Siva K Panguluri; Jared Tur; Jutaro Fukumoto; Wei Deng; Kevin B Sneed; Narasaiah Kolliputi; Eric S Bennett; Srinivas M Tipparaju
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

2.  Angiotensin II and the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes.

Authors:  Chiung-Zuan Chiu; Bao-Wei Wang; Tun-Hui Chung; Kou-Gi Shyu
Journal:  Clin Sci (Lond)       Date:  2010-06-22       Impact factor: 6.124

3.  Increased mobilization of mesenchymal stem cells in patients with essential hypertension: the effect of left ventricular hypertrophy.

Authors:  Maria E Marketou; Fragiskos I Parthenakis; Athanasia Kalyva; Charalampos Pontikoglou; Spyros Maragkoudakis; Joanna E Kontaraki; Evangelos A Zacharis; Gregory Chlouverakis; Alexandros Patrianakos; Helen A Papadaki; Panos E Vardas
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-10-20       Impact factor: 3.738

4.  In search of novel targets for heart disease: myocardin and myocardin-related transcriptional cofactors.

Authors:  Alexander T Mikhailov; Mario Torrado
Journal:  Biochem Res Int       Date:  2012-05-17

5.  Targeted gene-silencing reveals the functional significance of myocardin signaling in the failing heart.

Authors:  Mario Torrado; Raquel Iglesias; Alberto Centeno; Eduardo López; Alexander T Mikhailov
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

Review 6.  Myocardin in biology and disease.

Authors:  Joseph M Miano
Journal:  J Biomed Res       Date:  2014-12-25

7.  Establishment of a prediction model of changing trends in cardiac hypertrophy disease based on microarray data screening.

Authors:  Caiyan Ma; Yongjun Ying; Tianjie Zhang; Wei Zhang; Hui Peng; Xufeng Cheng; Lin Xu; Hong Tong
Journal:  Exp Ther Med       Date:  2016-02-24       Impact factor: 2.447

8.  The Formin, DIAPH1, is a Key Modulator of Myocardial Ischemia/Reperfusion Injury.

Authors:  Karen M O'Shea; Radha Ananthakrishnan; Qing Li; Nosirudeen Quadri; Devi Thiagarajan; Gopalkrishna Sreejit; Lingjie Wang; Hylde Zirpoli; Juan Francisco Aranda; Arthur S Alberts; Ann Marie Schmidt; Ravichandran Ramasamy
Journal:  EBioMedicine       Date:  2017-11-21       Impact factor: 8.143

9.  Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy.

Authors:  Shota Sasagawa; Yuhei Nishimura; Shiko Okabe; Soichiro Murakami; Yoshifumi Ashikawa; Mizuki Yuge; Koki Kawaguchi; Reiko Kawase; Ryuji Okamoto; Masaaki Ito; Toshio Tanaka
Journal:  Front Pharmacol       Date:  2016-06-14       Impact factor: 5.810

Review 10.  Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives.

Authors:  Maria E Marketou; Fragiskos Parthenakis; Panos E Vardas
Journal:  Stem Cells Int       Date:  2015-12-20       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.